GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBMFF) » Definitions » Selling, General, & Admin. Expense

Sino Biopharmaceutical (Sino Biopharmaceutical) Selling, General, & Admin. Expense : $1,547 Mil (TTM As of Jun. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Sino Biopharmaceutical Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Sino Biopharmaceutical's selling, general, & admin. expense for the six months ended in Jun. 2023 was $900 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2023 was $1,547 Mil.


Sino Biopharmaceutical Selling, General, & Admin. Expense Historical Data

The historical data trend for Sino Biopharmaceutical's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Selling, General, & Admin. Expense Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,681.99 1,778.26 1,994.51 1,802.14 1,549.91

Sino Biopharmaceutical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 928.17 1,035.65 807.57 899.88 647.36

Competitive Comparison of Sino Biopharmaceutical's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Sino Biopharmaceutical's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's Selling, General, & Admin. Expense falls into.



Sino Biopharmaceutical Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1,547 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sino Biopharmaceutical  (OTCPK:SBMFF) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Sino Biopharmaceutical Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical (Sino Biopharmaceutical) Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (Sino Biopharmaceutical) Headlines

From GuruFocus

Matthews China Fund 3rd Quarter Commentary

By Holly LaFon Holly LaFon 10-19-2017

Value Idea Contest: Sino Biopharmaceutical

By Matthew Sipos Matthew Sipos 01-10-2019

Matthews China Fund Comments on Sino Biopharmaceutical

By Sydnee Gatewood Sydnee Gatewood 10-25-2019

GuruFocus Value Idea Contest Sees 2 Winners!

By Holly LaFon Holly LaFon 07-12-2019

Matthews China Fund Comments on Sino Biopharmaceutical

By Vera Yuan Vera Yuan 10-20-2014

Matthews China Fund Comments on Sino Biopharmaceutical

By Sydnee Gatewood Sydnee Gatewood 01-28-2020